In July, Leach was tapped to take the CEO role permanently at the start of 2026 as part of Dexcom’s planned succession ...
Mike Kratky, an analyst from Leerink Partners, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target was lowered to $87.00. Mike Kratky’s rating is based on ...
Matthew Taylor, an analyst from Jefferies, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target remains the same with $100.00. Discover outperforming stocks and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback